RTHP-20. EVALUATION OF RADIATION THERAPY TECHNOLOGY AND DOSIMETRY IMPACT ON TREATMENT OUTCOME FOR GLIOBLASTOMA PATIENTS Article Swipe
Per Munck af Rosenschöld
,
Ian Law
,
Svend Aage Engelholm
,
Aida Muhic
,
Michael Lundemann
,
Henrik Roed
,
Kirsten Grunnet
,
Hans Skovgaard Poulsen
·
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.1093/neuonc/now212.746
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.1093/neuonc/now212.746
We sought to assess the impact of the clinical introduction of new radiation therapy technologies on the outcome for glioblastoma patients. Newly diagnosed glioblastoma patients receiving 60 Gy with concomitant and adjuvant temozolomide in the period 2005-2014 were analyzed. Gross tumor volume (GTV) and a clinical target volume by addition of up to 2 cm margin were defined based on MRI (N=522). A subset of patients (N=188) had a biological target volume (BTV) defined based on amino-acid 18F-Flouro-ethyl-tyrosine positron emission tomography (FET-PET) scanning. The patients’ target volumes were treated using conformal radiation therapy (CRT, N=159) or volumetric modulated arc therapy (VMAT) with hippocampal sparing and daily image-guided radiation therapy (IGRT, N=322). Progression-free survival (PFS) was assessed using the McDonald criteria. Associations between dosimetry data, treatment technology, PFS and overall survival (OS) were explored. Average brain dose was lower for patients treated with VMAT compared to CRT (p<0.001, Mann-Whitney). The Kaplan-Meier estimate of PFS and OS was not influenced by use of CRT, VMAT and FET-PET technology (log-rank), and was 7 and 15 months, respectively, for the whole cohort. Univariate Cox models revealed correlation of higher average brain dose, average brainstem dose, GTV and BTV (p<0.002), and left hippocampus (p=0.017) with lower OS. Average brain dose was statistically significant in multivariate Cox models for the whole cohort and VMAT treated patients (HR=1.04, p<0.001). For patients with FET-PET-guided RT, average dose to brainstem (HR=1.025, p=0.001) and BTV (HR=1.006, p=0.007) was significant. Average brain and brainstem dose as well as BTV were strongly associated with OS, and might aid prognostication. VMAT and IGRT technology allowed for reduction of doses to healthy brain, including the hippocampi, which may reduce toxicity and preserve cognition. The benefit of VMAT and IGRT technology was not offset by a reduction of PFS or OS.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/neuonc/now212.746
- https://academic.oup.com/neuro-oncology/article-pdf/18/suppl_6/vi178/9645483/now212.746.pdf
- OA Status
- bronze
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2588061632
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2588061632Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/neuonc/now212.746Digital Object Identifier
- Title
-
RTHP-20. EVALUATION OF RADIATION THERAPY TECHNOLOGY AND DOSIMETRY IMPACT ON TREATMENT OUTCOME FOR GLIOBLASTOMA PATIENTSWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2016Year of publication
- Publication date
-
2016-11-01Full publication date if available
- Authors
-
Per Munck af Rosenschöld, Ian Law, Svend Aage Engelholm, Aida Muhic, Michael Lundemann, Henrik Roed, Kirsten Grunnet, Hans Skovgaard PoulsenList of authors in order
- Landing page
-
https://doi.org/10.1093/neuonc/now212.746Publisher landing page
- PDF URL
-
https://academic.oup.com/neuro-oncology/article-pdf/18/suppl_6/vi178/9645483/now212.746.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/neuro-oncology/article-pdf/18/suppl_6/vi178/9645483/now212.746.pdfDirect OA link when available
- Concepts
-
Medicine, Nuclear medicine, Radiation therapy, Temozolomide, Cohort, Dosimetry, Concomitant, Proportional hazards model, Univariate analysis, Radiosurgery, Oncology, Internal medicine, Multivariate analysisTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2588061632 |
|---|---|
| doi | https://doi.org/10.1093/neuonc/now212.746 |
| ids.doi | https://doi.org/10.1093/neuonc/now212.746 |
| ids.mag | 2588061632 |
| ids.openalex | https://openalex.org/W2588061632 |
| fwci | 0.0 |
| type | article |
| title | RTHP-20. EVALUATION OF RADIATION THERAPY TECHNOLOGY AND DOSIMETRY IMPACT ON TREATMENT OUTCOME FOR GLIOBLASTOMA PATIENTS |
| biblio.issue | suppl_6 |
| biblio.volume | 18 |
| biblio.last_page | vi178 |
| biblio.first_page | vi178 |
| topics[0].id | https://openalex.org/T10129 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9724000096321106 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2716 |
| topics[0].subfield.display_name | Genetics |
| topics[0].display_name | Glioma Diagnosis and Treatment |
| topics[1].id | https://openalex.org/T10449 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9194999933242798 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2740 |
| topics[1].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[1].display_name | Renal cell carcinoma treatment |
| is_xpac | False |
| apc_list.value | 4612 |
| apc_list.currency | USD |
| apc_list.value_usd | 4612 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8314476013183594 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2989005 |
| concepts[1].level | 1 |
| concepts[1].score | 0.6847735643386841 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q214963 |
| concepts[1].display_name | Nuclear medicine |
| concepts[2].id | https://openalex.org/C509974204 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6219584941864014 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q180507 |
| concepts[2].display_name | Radiation therapy |
| concepts[3].id | https://openalex.org/C2777389519 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5845507383346558 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q425088 |
| concepts[3].display_name | Temozolomide |
| concepts[4].id | https://openalex.org/C72563966 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5639523863792419 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1303415 |
| concepts[4].display_name | Cohort |
| concepts[5].id | https://openalex.org/C75088862 |
| concepts[5].level | 2 |
| concepts[5].score | 0.49671345949172974 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2291081 |
| concepts[5].display_name | Dosimetry |
| concepts[6].id | https://openalex.org/C2779384505 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4886989891529083 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q17007513 |
| concepts[6].display_name | Concomitant |
| concepts[7].id | https://openalex.org/C50382708 |
| concepts[7].level | 2 |
| concepts[7].score | 0.45685911178588867 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q223218 |
| concepts[7].display_name | Proportional hazards model |
| concepts[8].id | https://openalex.org/C144301174 |
| concepts[8].level | 3 |
| concepts[8].score | 0.44041240215301514 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q7893852 |
| concepts[8].display_name | Univariate analysis |
| concepts[9].id | https://openalex.org/C2780387249 |
| concepts[9].level | 3 |
| concepts[9].score | 0.4359606206417084 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q973234 |
| concepts[9].display_name | Radiosurgery |
| concepts[10].id | https://openalex.org/C143998085 |
| concepts[10].level | 1 |
| concepts[10].score | 0.3978477120399475 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[10].display_name | Oncology |
| concepts[11].id | https://openalex.org/C126322002 |
| concepts[11].level | 1 |
| concepts[11].score | 0.3843972682952881 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[11].display_name | Internal medicine |
| concepts[12].id | https://openalex.org/C38180746 |
| concepts[12].level | 2 |
| concepts[12].score | 0.3241470456123352 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q1952580 |
| concepts[12].display_name | Multivariate analysis |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8314476013183594 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/nuclear-medicine |
| keywords[1].score | 0.6847735643386841 |
| keywords[1].display_name | Nuclear medicine |
| keywords[2].id | https://openalex.org/keywords/radiation-therapy |
| keywords[2].score | 0.6219584941864014 |
| keywords[2].display_name | Radiation therapy |
| keywords[3].id | https://openalex.org/keywords/temozolomide |
| keywords[3].score | 0.5845507383346558 |
| keywords[3].display_name | Temozolomide |
| keywords[4].id | https://openalex.org/keywords/cohort |
| keywords[4].score | 0.5639523863792419 |
| keywords[4].display_name | Cohort |
| keywords[5].id | https://openalex.org/keywords/dosimetry |
| keywords[5].score | 0.49671345949172974 |
| keywords[5].display_name | Dosimetry |
| keywords[6].id | https://openalex.org/keywords/concomitant |
| keywords[6].score | 0.4886989891529083 |
| keywords[6].display_name | Concomitant |
| keywords[7].id | https://openalex.org/keywords/proportional-hazards-model |
| keywords[7].score | 0.45685911178588867 |
| keywords[7].display_name | Proportional hazards model |
| keywords[8].id | https://openalex.org/keywords/univariate-analysis |
| keywords[8].score | 0.44041240215301514 |
| keywords[8].display_name | Univariate analysis |
| keywords[9].id | https://openalex.org/keywords/radiosurgery |
| keywords[9].score | 0.4359606206417084 |
| keywords[9].display_name | Radiosurgery |
| keywords[10].id | https://openalex.org/keywords/oncology |
| keywords[10].score | 0.3978477120399475 |
| keywords[10].display_name | Oncology |
| keywords[11].id | https://openalex.org/keywords/internal-medicine |
| keywords[11].score | 0.3843972682952881 |
| keywords[11].display_name | Internal medicine |
| keywords[12].id | https://openalex.org/keywords/multivariate-analysis |
| keywords[12].score | 0.3241470456123352 |
| keywords[12].display_name | Multivariate analysis |
| language | en |
| locations[0].id | doi:10.1093/neuonc/now212.746 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S106908163 |
| locations[0].source.issn | 1522-8517, 1523-5866 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1522-8517 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Neuro-Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | |
| locations[0].pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/18/suppl_6/vi178/9645483/now212.746.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Neuro-Oncology |
| locations[0].landing_page_url | https://doi.org/10.1093/neuonc/now212.746 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5015986025 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-5988-8994 |
| authorships[0].author.display_name | Per Munck af Rosenschöld |
| authorships[0].countries | DK |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2802709434 |
| authorships[0].affiliations[0].raw_affiliation_string | Rigshospitalet, Dept. of Oncology, Copenhagen, Denmark, |
| authorships[0].institutions[0].id | https://openalex.org/I2802709434 |
| authorships[0].institutions[0].ror | https://ror.org/03mchdq19 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I2802567020, https://openalex.org/I2802709434, https://openalex.org/I4210145385 |
| authorships[0].institutions[0].country_code | DK |
| authorships[0].institutions[0].display_name | Rigshospitalet |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Per Munck af Rosenschold |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Rigshospitalet, Dept. of Oncology, Copenhagen, Denmark, |
| authorships[1].author.id | https://openalex.org/A5007149982 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-9644-7496 |
| authorships[1].author.display_name | Ian Law |
| authorships[1].countries | DK |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2802709434 |
| authorships[1].affiliations[0].raw_affiliation_string | Rigshospitalet, Dept of Clinical Physiology, Nuclear Medicine and PET, Copenhagen, Denmark, |
| authorships[1].institutions[0].id | https://openalex.org/I2802709434 |
| authorships[1].institutions[0].ror | https://ror.org/03mchdq19 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I2802567020, https://openalex.org/I2802709434, https://openalex.org/I4210145385 |
| authorships[1].institutions[0].country_code | DK |
| authorships[1].institutions[0].display_name | Rigshospitalet |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Ian Law |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Rigshospitalet, Dept of Clinical Physiology, Nuclear Medicine and PET, Copenhagen, Denmark, |
| authorships[2].author.id | https://openalex.org/A5108549624 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Svend Aage Engelholm |
| authorships[2].countries | DK |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I2802709434 |
| authorships[2].affiliations[0].raw_affiliation_string | Rigshospitalet, Dept of Oncology, Copenhagen, Denmark, |
| authorships[2].institutions[0].id | https://openalex.org/I2802709434 |
| authorships[2].institutions[0].ror | https://ror.org/03mchdq19 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I2802567020, https://openalex.org/I2802709434, https://openalex.org/I4210145385 |
| authorships[2].institutions[0].country_code | DK |
| authorships[2].institutions[0].display_name | Rigshospitalet |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Svend Aage Engelholm |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Rigshospitalet, Dept of Oncology, Copenhagen, Denmark, |
| authorships[3].author.id | https://openalex.org/A5069496557 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-1195-9500 |
| authorships[3].author.display_name | Aida Muhic |
| authorships[3].countries | DK |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2802709434 |
| authorships[3].affiliations[0].raw_affiliation_string | Dept of Oncology, Rigshospitalet, Copenhagen, Denmark, |
| authorships[3].institutions[0].id | https://openalex.org/I2802709434 |
| authorships[3].institutions[0].ror | https://ror.org/03mchdq19 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I2802567020, https://openalex.org/I2802709434, https://openalex.org/I4210145385 |
| authorships[3].institutions[0].country_code | DK |
| authorships[3].institutions[0].display_name | Rigshospitalet |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Aida Muhic |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Dept of Oncology, Rigshospitalet, Copenhagen, Denmark, |
| authorships[4].author.id | https://openalex.org/A5088379714 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-4216-5757 |
| authorships[4].author.display_name | Michael Lundemann |
| authorships[4].countries | DK |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I2802709434 |
| authorships[4].affiliations[0].raw_affiliation_string | Rigshopitalet, Dept of Oncology, Copenhagen, Denmark |
| authorships[4].institutions[0].id | https://openalex.org/I2802709434 |
| authorships[4].institutions[0].ror | https://ror.org/03mchdq19 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I2802567020, https://openalex.org/I2802709434, https://openalex.org/I4210145385 |
| authorships[4].institutions[0].country_code | DK |
| authorships[4].institutions[0].display_name | Rigshospitalet |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Michael Lundemann |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Rigshopitalet, Dept of Oncology, Copenhagen, Denmark |
| authorships[5].author.id | https://openalex.org/A5050072046 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Henrik Roed |
| authorships[5].countries | DK |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I2802709434 |
| authorships[5].affiliations[0].raw_affiliation_string | Rigshospitalet, Dept of Oncology, Copenhagen, Denmark, |
| authorships[5].institutions[0].id | https://openalex.org/I2802709434 |
| authorships[5].institutions[0].ror | https://ror.org/03mchdq19 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I2802567020, https://openalex.org/I2802709434, https://openalex.org/I4210145385 |
| authorships[5].institutions[0].country_code | DK |
| authorships[5].institutions[0].display_name | Rigshospitalet |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Henrik Roed |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Rigshospitalet, Dept of Oncology, Copenhagen, Denmark, |
| authorships[6].author.id | https://openalex.org/A5007297826 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Kirsten Grunnet |
| authorships[6].countries | DK |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I2802709434 |
| authorships[6].affiliations[0].raw_affiliation_string | Rigshospitalet, Dept of Oncology, Copenhagen, Denmark, |
| authorships[6].institutions[0].id | https://openalex.org/I2802709434 |
| authorships[6].institutions[0].ror | https://ror.org/03mchdq19 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I2802567020, https://openalex.org/I2802709434, https://openalex.org/I4210145385 |
| authorships[6].institutions[0].country_code | DK |
| authorships[6].institutions[0].display_name | Rigshospitalet |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Kirsten Grunnet |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Rigshospitalet, Dept of Oncology, Copenhagen, Denmark, |
| authorships[7].author.id | https://openalex.org/A5004172331 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-9801-5387 |
| authorships[7].author.display_name | Hans Skovgaard Poulsen |
| authorships[7].countries | DK |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I2802709434 |
| authorships[7].affiliations[0].raw_affiliation_string | Rigshospitalet, Dept of Oncology, Copenhagen, Denmark, |
| authorships[7].institutions[0].id | https://openalex.org/I2802709434 |
| authorships[7].institutions[0].ror | https://ror.org/03mchdq19 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I2802567020, https://openalex.org/I2802709434, https://openalex.org/I4210145385 |
| authorships[7].institutions[0].country_code | DK |
| authorships[7].institutions[0].display_name | Rigshospitalet |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Hans Skovgaard Poulsen |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Rigshospitalet, Dept of Oncology, Copenhagen, Denmark, |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/neuro-oncology/article-pdf/18/suppl_6/vi178/9645483/now212.746.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | RTHP-20. EVALUATION OF RADIATION THERAPY TECHNOLOGY AND DOSIMETRY IMPACT ON TREATMENT OUTCOME FOR GLIOBLASTOMA PATIENTS |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10129 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9724000096321106 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2716 |
| primary_topic.subfield.display_name | Genetics |
| primary_topic.display_name | Glioma Diagnosis and Treatment |
| related_works | https://openalex.org/W2235074116, https://openalex.org/W2123602693, https://openalex.org/W2022503084, https://openalex.org/W2182202988, https://openalex.org/W145662657, https://openalex.org/W4389442266, https://openalex.org/W4248982232, https://openalex.org/W2109868410, https://openalex.org/W3112002494, https://openalex.org/W2023427764 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1093/neuonc/now212.746 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S106908163 |
| best_oa_location.source.issn | 1522-8517, 1523-5866 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1522-8517 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Neuro-Oncology |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/18/suppl_6/vi178/9645483/now212.746.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Neuro-Oncology |
| best_oa_location.landing_page_url | https://doi.org/10.1093/neuonc/now212.746 |
| primary_location.id | doi:10.1093/neuonc/now212.746 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S106908163 |
| primary_location.source.issn | 1522-8517, 1523-5866 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1522-8517 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Neuro-Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | |
| primary_location.pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/18/suppl_6/vi178/9645483/now212.746.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Neuro-Oncology |
| primary_location.landing_page_url | https://doi.org/10.1093/neuonc/now212.746 |
| publication_date | 2016-11-01 |
| publication_year | 2016 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 53 |
| abstract_inverted_index.7 | 169 |
| abstract_inverted_index.A | 62 |
| abstract_inverted_index.a | 44, 68, 290 |
| abstract_inverted_index.15 | 171 |
| abstract_inverted_index.60 | 26 |
| abstract_inverted_index.Gy | 27 |
| abstract_inverted_index.OS | 154 |
| abstract_inverted_index.We | 0 |
| abstract_inverted_index.as | 244, 246 |
| abstract_inverted_index.by | 48, 158, 289 |
| abstract_inverted_index.cm | 54 |
| abstract_inverted_index.in | 33, 208 |
| abstract_inverted_index.of | 6, 10, 50, 64, 151, 160, 183, 264, 281, 292 |
| abstract_inverted_index.on | 15, 59, 75 |
| abstract_inverted_index.or | 95, 294 |
| abstract_inverted_index.to | 2, 52, 144, 229, 266 |
| abstract_inverted_index.up | 51 |
| abstract_inverted_index.BTV | 193, 234, 247 |
| abstract_inverted_index.CRT | 145 |
| abstract_inverted_index.Cox | 179, 210 |
| abstract_inverted_index.For | 222 |
| abstract_inverted_index.GTV | 191 |
| abstract_inverted_index.MRI | 60 |
| abstract_inverted_index.OS, | 252 |
| abstract_inverted_index.OS. | 201, 295 |
| abstract_inverted_index.PFS | 126, 152, 293 |
| abstract_inverted_index.RT, | 226 |
| abstract_inverted_index.The | 83, 148, 279 |
| abstract_inverted_index.aid | 255 |
| abstract_inverted_index.and | 30, 43, 104, 127, 153, 163, 167, 170, 192, 195, 216, 233, 241, 253, 258, 276, 283 |
| abstract_inverted_index.arc | 98 |
| abstract_inverted_index.for | 18, 138, 174, 212, 262 |
| abstract_inverted_index.had | 67 |
| abstract_inverted_index.may | 273 |
| abstract_inverted_index.new | 11 |
| abstract_inverted_index.not | 156, 287 |
| abstract_inverted_index.the | 4, 7, 16, 34, 117, 175, 213, 270 |
| abstract_inverted_index.use | 159 |
| abstract_inverted_index.was | 114, 136, 155, 168, 205, 237, 286 |
| abstract_inverted_index.(OS) | 130 |
| abstract_inverted_index.CRT, | 161 |
| abstract_inverted_index.IGRT | 259, 284 |
| abstract_inverted_index.VMAT | 142, 162, 217, 257, 282 |
| abstract_inverted_index.dose | 135, 204, 228, 243 |
| abstract_inverted_index.left | 196 |
| abstract_inverted_index.well | 245 |
| abstract_inverted_index.were | 37, 56, 87, 131, 248 |
| abstract_inverted_index.with | 28, 101, 141, 199, 224, 251 |
| abstract_inverted_index.(BTV) | 72 |
| abstract_inverted_index.(CRT, | 93 |
| abstract_inverted_index.(GTV) | 42 |
| abstract_inverted_index.(PFS) | 113 |
| abstract_inverted_index.Gross | 39 |
| abstract_inverted_index.Newly | 21 |
| abstract_inverted_index.based | 58, 74 |
| abstract_inverted_index.brain | 134, 186, 203, 240 |
| abstract_inverted_index.daily | 105 |
| abstract_inverted_index.data, | 123 |
| abstract_inverted_index.dose, | 187, 190 |
| abstract_inverted_index.doses | 265 |
| abstract_inverted_index.lower | 137, 200 |
| abstract_inverted_index.might | 254 |
| abstract_inverted_index.tumor | 40 |
| abstract_inverted_index.using | 89, 116 |
| abstract_inverted_index.which | 272 |
| abstract_inverted_index.whole | 176, 214 |
| abstract_inverted_index.(IGRT, | 109 |
| abstract_inverted_index.(VMAT) | 100 |
| abstract_inverted_index.N=159) | 94 |
| abstract_inverted_index.assess | 3 |
| abstract_inverted_index.brain, | 268 |
| abstract_inverted_index.cohort | 215 |
| abstract_inverted_index.higher | 184 |
| abstract_inverted_index.impact | 5 |
| abstract_inverted_index.margin | 55 |
| abstract_inverted_index.models | 180, 211 |
| abstract_inverted_index.offset | 288 |
| abstract_inverted_index.period | 35 |
| abstract_inverted_index.reduce | 274 |
| abstract_inverted_index.sought | 1 |
| abstract_inverted_index.subset | 63 |
| abstract_inverted_index.target | 46, 70, 85 |
| abstract_inverted_index.volume | 41, 47, 71 |
| abstract_inverted_index.(N=188) | 66 |
| abstract_inverted_index.Average | 133, 202, 239 |
| abstract_inverted_index.FET-PET | 164 |
| abstract_inverted_index.N=322). | 110 |
| abstract_inverted_index.allowed | 261 |
| abstract_inverted_index.average | 185, 188, 227 |
| abstract_inverted_index.benefit | 280 |
| abstract_inverted_index.between | 121 |
| abstract_inverted_index.cohort. | 177 |
| abstract_inverted_index.defined | 57, 73 |
| abstract_inverted_index.healthy | 267 |
| abstract_inverted_index.months, | 172 |
| abstract_inverted_index.outcome | 17 |
| abstract_inverted_index.overall | 128 |
| abstract_inverted_index.sparing | 103 |
| abstract_inverted_index.therapy | 13, 92, 99, 108 |
| abstract_inverted_index.treated | 88, 140, 218 |
| abstract_inverted_index.volumes | 86 |
| abstract_inverted_index.(N=522). | 61 |
| abstract_inverted_index.McDonald | 118 |
| abstract_inverted_index.addition | 49 |
| abstract_inverted_index.adjuvant | 31 |
| abstract_inverted_index.assessed | 115 |
| abstract_inverted_index.clinical | 8, 45 |
| abstract_inverted_index.compared | 143 |
| abstract_inverted_index.emission | 79 |
| abstract_inverted_index.estimate | 150 |
| abstract_inverted_index.p=0.001) | 232 |
| abstract_inverted_index.p=0.007) | 236 |
| abstract_inverted_index.patients | 24, 65, 139, 219, 223 |
| abstract_inverted_index.positron | 78 |
| abstract_inverted_index.preserve | 277 |
| abstract_inverted_index.revealed | 181 |
| abstract_inverted_index.strongly | 249 |
| abstract_inverted_index.survival | 112, 129 |
| abstract_inverted_index.toxicity | 275 |
| abstract_inverted_index.(FET-PET) | 81 |
| abstract_inverted_index.(HR=1.04, | 220 |
| abstract_inverted_index.(p<0.001, | 146 |
| abstract_inverted_index.(p=0.017) | 198 |
| abstract_inverted_index.2005-2014 | 36 |
| abstract_inverted_index.analyzed. | 38 |
| abstract_inverted_index.brainstem | 189, 230, 242 |
| abstract_inverted_index.conformal | 90 |
| abstract_inverted_index.criteria. | 119 |
| abstract_inverted_index.diagnosed | 22 |
| abstract_inverted_index.dosimetry | 122 |
| abstract_inverted_index.explored. | 132 |
| abstract_inverted_index.including | 269 |
| abstract_inverted_index.modulated | 97 |
| abstract_inverted_index.p<0.001). | 221 |
| abstract_inverted_index.patients. | 20 |
| abstract_inverted_index.radiation | 12, 91, 107 |
| abstract_inverted_index.receiving | 25 |
| abstract_inverted_index.reduction | 263, 291 |
| abstract_inverted_index.scanning. | 82 |
| abstract_inverted_index.treatment | 124 |
| abstract_inverted_index.(HR=1.006, | 235 |
| abstract_inverted_index.(HR=1.025, | 231 |
| abstract_inverted_index.(p<0.002), | 194 |
| abstract_inverted_index.Univariate | 178 |
| abstract_inverted_index.amino-acid | 76 |
| abstract_inverted_index.associated | 250 |
| abstract_inverted_index.biological | 69 |
| abstract_inverted_index.cognition. | 278 |
| abstract_inverted_index.influenced | 157 |
| abstract_inverted_index.technology | 165, 260, 285 |
| abstract_inverted_index.tomography | 80 |
| abstract_inverted_index.volumetric | 96 |
| abstract_inverted_index.(log-rank), | 166 |
| abstract_inverted_index.concomitant | 29 |
| abstract_inverted_index.correlation | 182 |
| abstract_inverted_index.hippocampal | 102 |
| abstract_inverted_index.hippocampi, | 271 |
| abstract_inverted_index.hippocampus | 197 |
| abstract_inverted_index.patients’ | 84 |
| abstract_inverted_index.significant | 207 |
| abstract_inverted_index.technology, | 125 |
| abstract_inverted_index.Associations | 120 |
| abstract_inverted_index.Kaplan-Meier | 149 |
| abstract_inverted_index.glioblastoma | 19, 23 |
| abstract_inverted_index.image-guided | 106 |
| abstract_inverted_index.introduction | 9 |
| abstract_inverted_index.multivariate | 209 |
| abstract_inverted_index.significant. | 238 |
| abstract_inverted_index.technologies | 14 |
| abstract_inverted_index.temozolomide | 32 |
| abstract_inverted_index.respectively, | 173 |
| abstract_inverted_index.statistically | 206 |
| abstract_inverted_index.FET-PET-guided | 225 |
| abstract_inverted_index.Mann-Whitney). | 147 |
| abstract_inverted_index.Progression-free | 111 |
| abstract_inverted_index.prognostication. | 256 |
| abstract_inverted_index.18F-Flouro-ethyl-tyrosine | 77 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 8 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7599999904632568 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.19921014 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |